Abstract
Introduction: Antithymocyte globulin (ATG) has been demonstrated to reduce the incidence of graft-versus-host disease (GVHD); however, it remains controversial whether these gains are offset by an increase in relapse. Methods: We conducted a retrospective historical control study consisting of patients (n = 210) who underwent myeloablative allogeneic hematopoietic stem-cell transplantation (HSCT) from 2014 to 2020. Results: The incidence of acute GVHD was lower in the ATG group (51.4%) than the non-ATG group (control) (70.0%, p = 0.010). The incidence of chronic GVHD was also lower in the ATG group at 1-year (36.4% vs. 62.9%, p < 0.001) and 2-year (40.0% vs. 65.7%, p < 0.001) post-HSCT. The mortality due to GVHD was higher in the control (18.5%) than the ATG group (4.3%; p = 0.024). The severe GVHD-relapse-free survival was higher in the ATG group (36.4%) than the control (12.9%; p < 0.001). Nevertheless, the 2-year overall survival was similar. Conclusion: Our results confirm the effectiveness of ATG in prevention of GVHD in the real-world setting and enhanced GVHD-free survival. An important result is the equalization of overall survival between the ATG and control groups at 1- and 2-year post-HSCT and implies that earlier GVHD-associated mortality may be offset by later relapse mortality producing similar overall survival over time.
Journal Section:
Original Paper
References
1.
Pidala
J
, Kurland
B
, Chai
X
, Majhail
N
, Weisdorf
DJ
, Pavletic
S
, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium
. Blood
. 2011
;117
(17
):4651
–7
. 2.
Inamoto
Y
, Martin
PJ
, Storer
BE
, Palmer
J
, Weisdorf
DJ
, Pidala
J
, et al. Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease
. Haematologica
. 2014
;99
(10
):1618
–23
. 3.
Martin
P
. How I treat steroid refractory acute graft vs host disease
. Blood
. 2020
;135
(19
):1630
–8
.4.
Nash
RA
, Antin
JH
, Karanes
C
, Fay
JW
, Avalos
BR
, Yeager
AM
, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors
. Blood
. 2000
;96
(6
):2062
–8
.5.
Lee
SJ
, Vogelsang
G
, Flowers
ME
. Chronic graft-versus-host disease
. Biol Blood Marrow Transplant
. 2003
;9
(4
):215
–33
. 6.
Sarantopoulos
S
, Cardones
AR
, Sullivan
KM
. How I treat refractory chronic graft-versus-host disease
. Blood
. 2019
;133
(11
):1191
–200
. 7.
Storb
R
, Gluckman
E
, Thomas
ED
, Buckner
CD
, Cliff
RA
, Fefer
A
, et al. Treatment of established human graft-versus-host disease by antithymocyte globulin
. Blood
. 1974
;44
(1
):57
–75
. 8.
Mohty
M
. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond
. Leukemia
. 2007
;21
(7
):1387
–94
. 9.
Bacigalupo
A
, Lamparelli
T
, Barisione
G
, Bruzzi
P
, Guidi
S
, Alessandrino
PE
, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation
. Biol Blood Marrow Transplant
. 2006
;12
(5
):560
–5
. 10.
Finke
J
, Bethge
WA
, Schmoor
C
, Ottinger
HD
; ATG-Fresenius Trial Group
; Stelljes
M
, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
. Lancet Oncol
. 2009
;10
(9
):855
–64
. 11.
Theurich
S
, Fischmann
H
, Chakupurakal
G
, Shimabukuro-Vornhagen
A
, Chemnitz
JM
, Holtick
U
, et al. Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis-A systematic review and meta-analysis
. Crit Rev Oncol Hematol
. 2013
;88
(1
):178
–86
. 12.
Kröger
N
, Solano
C
, Wolschke
C
, Bandini
G
, Patriarca
F
, Pini
M
, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease
. N Engl J Med
. 2016
;374
(1
):43
–53
. 13.
Walker
I
, Panzarella
T
, Couban
S
, Couture
F
, Devins
G
, Elemary
M
, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial
. Lancet Oncol
. 2016
;17
(2
):164
–73
. 14.
Walker
I
, Panzarella
T
, Couban
S
, Couture
F
, Devins
G
, Elemary
M
, et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial
. Lancet Haematol
. 2020
;7
(2
):e100
–11
. 15.
Soiffer
RJ
, Kim
HT
, McGuirk
J
, Horwitz
ME
, Johnston
L
, Patnaik
MM
, et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation
. Al J Clin Oncol
. 2017
;35
(36
):4003
–11
. 16.
Arai
Y
, Jo
T
, Matsui
H
, Kondo
T
, Takaori-Kondo
A
. Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis
. Leuk Lymphoma
. 2017
;58
(8
):1840
–8
. 17.
Bacigalupo
A
, Lamparelli
T
, Bruzzi
P
, Guidi
S
, Alessandrino
PE
, di Bartolomeo
P
, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)
. Blood
. 2001
;98
(10
):2942
–7
. 18.
Butera
S
, Cerrano
M
, Brunello
L
, Dellacasa
CM
, Faraci
DG
, Vassallo
S
, et al. Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience
. Ann Hematol
. 2021
;100
(7
):1837
–47
. 19.
Rowlings
PA
, Przepiorka
D
, Klein
JP
, Gale
RP
, Passweg
JR
, Henslee-Downey
PJ
, et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade
. Br J Haematol
. 1997
;97
(4
):855
–64
. 20.
Martin
PJ
, Lee
SJ
, Przepiorka
D
, Horowitz
MM
, Koreth
J
, Vogelsang
GB
, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: VI. The 2014 clinical trial design working group report
. Biol Blood Marrow Transplant
. 2015
;21
(8
):1343
–59
. 21.
Battipaglia
G
, Labopin
M
, Kröger
N
, Vitek
A
, Afanasyev
B
, Hilgendorf
I
, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation
. Blood
. 2019
;134
(11
):892
–9
. 22.
Kumar
A
, Reljic
T
, Hamadani
M
, Mohty
M
, Kharfan-Dabaja
MA
. Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis
. Bone Marrow Transplant
. 2019
;54
(7
):1094
–106
. 23.
Bartelink
IH
, Belitser
SV
, Knibbe
CA
, Danhof
M
, de Pagter
AJ
, Egberts
TCG
, et al. Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children
. Biol Blood Marrow Transplant
. 2013
;19
(2
):305
–13
. 24.
Lindemans
CA
, Chiesa
R
, Amrolia
PJ
, Rao
K
, Nikolajeva
O
, de Wildt
A
, et al. Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome
. Blood
. 2014
;123
(1
):126
–32
. 25.
Hiwarkar
P
, Gaspar
HB
, Gilmour
K
, Jagani
M
, Chiesa
R
, Bennett-Rees
N
, et al. Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients
. Bone Marrow Transplant
. 2013
;48
(6
):803
–8
. 26.
Cho
BS
, Min
GJ
, Park
SS
, Yoon
SY
, Park
S
, Jeon
YW
, et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor
. Am J Hematol
. 2021
;96
(11
):1441
–9
. 27.
Kolb
HJ
, Mittermüller
J
, Clemm
C
, Holler
E
, Ledderose
G
, Brehm
G
, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
. Blood
. 1990
;76
(12
):2462
–5
. 28.
Collins
RHJ
, Goldstein
S
, Giralt
S
, Levine
J
, Porter
D
, Drobyski
W
, et al. Donor leukocyte infusions in acute lymphocytic leukemia
. Bone Marrow Transplant
. 2000
;26
(5
):511
–6
. 29.
Michallet
AS
, Nicolini
F
, Fürst
S
, Le
QH
, Dubois
V
, Hayette
S
, et al. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT)
. Bone Marrow Transplant
. 2005
;35
(6
):601
–8
. 30.
Maurer
K
, Antin
JH
. The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy
. Front Immunol
. 2024
;15
:1328858
. 31.
Gao
F
, Zhang
J
, Hu
J
, Lin
L
, Xu
Y
. Post-transplant cyclophosphamide versus antithymocyte globulin in allogeneic hematopoietic cell transplantation: a meta-analysis
. Ann Hematol
. 2021
;100
(2
):529
–40
. 32.
Brissot
E
, Labopin
M
, Moiseev
I
, Cornelissen
JJ
, Meijer
E
, Van Gorkom
G
, et al. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors
. J Hematol Oncol
. 2020
;13
(1
):87
. 33.
Battipaglia
G
, Labopin
M
, Hamladji
RM
, Blaise
D
, Chevallier
P
, Brissot
E
, et al. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: a retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
. Cancer
. 2021
;127
(2
):209
–18
. 34.
Law
AD
, Salas
MQ
, Lam
W
, Michelis
FV
, Thyagu
S
, Kim
DDH
, et al. Reduced-Intensity conditioning and dual T lymphocyte suppression with antithymocyte globulin and post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplants for hematological malignancies
. Biol Blood Marrow Transplant
. 2018
;24
(11
):2259
–64
. 35.
Salas
MQ
, Prem
S
, Atenafu
EG
, Datt Law
A
, Lam
W
, Al-Shaibani
Z
, et al. Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD
. Bone Marrow Transplant
. 2020
;55
(9
):1773
–83
. 36.
Zhou
X
, Cai
Y
, Yang
J
, Tong
Y
, Qiu
H
, Huang
C
, et al. Lower absolute lymphocyte count before conditioning predicts high relapse risk in patients after haploidentical peripheral blood stem cell transplantation with low dose anti-thymocyte globulin/post-transplant cyclophosphamide for GvHD Prophylaxis
. Cell Transplant
. 2022
;31
:9636897221079739
. 37.
Shichijo
T
, Fuji
S
, Nagler
A
, Bazarbachi
A
, Mohty
M
, Savani
BN
. Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose
. Bone Marrow Transplant
. 2020
;55
(3
):505
–22
. 38.
Wang
H
, Zhao
Y
, Fang
S
, Wang
L
, Peng
B
, Yang
J
, et al. Optimal active anti-thymocyte globulin exposure associated with minimum risk of virus reactivation and comparable acute graft-versus-host disease under adult myeloablative haploidentical peripheral blood stem cell transplantation
. Transplant Cell Ther
. 2022
;28
(6
):332.e1
–e10
. 39.
Admiraal
R
, van Kesteren
C
, Jol-van der Zijde
CM
, Lankester
AC
, Bierings
MB
, Egberts
TCG
, et al. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis
. Lancet Haematol
. 2015
;2
(5
):e194
–203
. 40.
Popow
I
, Leitner
J
, Grabmeier-Pfistershammer
K
, Majdic
O
, Zlabinger
GJ
, Kundi
M
, et al. A comprehensive and quantitative analysis of the major specificities in rabbit antithymocyte globulin preparations
. Am J Transplant
. 2013
;13
(12
):3103
–13
. 41.
Westphal
S
, Brinkmann
H
, Kalupa
M
, Wilke
A
, Seitz-Merwald
I
, Penack
O
. Anti-tumor effects of anti-T-cell globulin
. Exp Hematol
. 2014
;42
(10
):875
–82
. 42.
Chakupurakal
G
, Freudenberger
P
, Skoetz
N
, Ahr
H
, Theurich
S
. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults
. Cochrane Database Syst Rev
. 2023
;6
(6
):CD009159
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
